Lupin Ltd (LUPN.BO)

LUPN.BO on Bombay Stock Exchange

28 Apr 2017
Change (% chg)

Rs0.55 (+0.04%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for LUPN.BO


Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central... (more)


Beta: -0.02
Market Cap(Mil.): Rs619,214.81
Shares Outstanding(Mil.): 451.64
Dividend: 7.50
Yield (%): 0.55


  LUPN.BO Industry Sector
P/E (TTM): 21.22 29.41 30.38
EPS (TTM): 64.61 -- --
ROI: -- 13.85 13.36
ROE: -- 14.79 14.50

BRIEF-Lupin says Goa plant gets three 483 observations by USFDA

* Lupin clarifies on news item, "Lupin's Goa plant receives adverse FDA observations".

28 Apr 2017

BRIEF-Lupin gets FDA approval for hypertension treating drug

* Says Lupin receives FDA approval for generic benicar tablets

28 Apr 2017

BRIEF-Lupin launches generic Epzicom tablets in U.S.

* Says drug indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection

29 Mar 2017

BRIEF-Lupin Ltd gets FDA nod for generic Tobi inhalation solution

* Says lupin receives FDA approval for generic Tobi® inhalation solution

23 Mar 2017

BRIEF-Lupin Ltd launches generic Minastrin 24 Fe chewable tablets in U.S.

* Says Lupin launches generic Minastrin 24 Fe chewable tablets in the US

16 Mar 2017

BRIEF-Lupin launches its pain drug in the U.S.

* Says Lupin launches hydrocodone bitartrate and acetaminophen tablets in the U.S.

09 Mar 2017

BRIEF-Lupin launches generic drug to treat major depressive disorder

* Drug indicated to treat major depressive disorder, panic disorder, social anxiety disorder and premenstrual dysphoric disorder Source text: http://bit.ly/2n9awVy Further company coverage:

07 Mar 2017

BRIEF-Lupin announces U.S. launch of generic drug to treat depression

* Says tablets are indicated for the treatment of major depressive disorder Source text: http://bit.ly/2mgR90c Further company coverage:

02 Mar 2017

BRIEF-Lupin launches product for scalp inflammation treatment in the U.S.

* Says Lupin launches generic Temovate® Clobetasol Propionate scalp application in the US

01 Mar 2017

BRIEF-Lupin receives USFDA approval for pain relievers

* Received final approval for its Oxycodone and Acetaminophen tablets USP, 2.5 mg/325 mg, 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg from USFDA

28 Feb 2017

More From Around the Web

Earnings vs. Estimates